Assessment of success

NJ Niklas Dyrby Johansen
DM Daniel Modin
JN Joshua Nealon
SS Sandrine Samson
CS Camille Salamand
CL Carsten Schade Larsen
BC Brian L. Claggett
SS Scott D. Solomon
ML Martin J. Landray
GG Gunnar H. Gislason
LK Lars Køber
JJ Jens Ulrik Stæhr Jensen
PS Pradeesh Sivapalan
LV Lasse Skafte Vestergaard
PV Palle Valentiner-Branth
TK Tyra Grove Krause
TB Tor Biering-Sørensen
ask Ask a question
Favorite

Since this is the first trial ever conducted in Denmark to use the setup and design described in this report, the study team found it impossible to devise specific criteria for success with meaningful numerical cutoffs. Significant uncertainties pertaining primarily to the obtainment of approvals for this novel trial design from the Danish authorities and obtaining real-time access to registry data for a drug trial existed, leaving the study team wondering whether it would even be possible to initiate the trial. Due to this, the assessment of success will rely on an overall evaluation of the conduct of the trial including the obtainment of approvals, recruitment rate and success, randomization agreement, and reliability with regards to the registry-based obtainment of baseline characteristics, safety events, and clinical endpoints. This overall evaluation will be used by the study team as part of the decision on whether to progress to a fully powered trial. Any specific issues encountered during this feasibility trial will be addressed in the design of a fully powered trial, in case the study team should decide to progress.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A